NEWS |  January 19, 2023

Sense Neuro Diagnostics Awarded Arizona Innovation Challenge

Commercialization Opportunity Grows MedTech Startup’s Presence in Grand Canyon State

CINCINNATI, OH – January 19, 2023 – Sense Neuro Diagnostics is getting ready to participate in the  Arizona Commerce Authority Venture Ready Accelerator, an initiative that helps startups refine business  plans, improve go-to-market execution strategies, and increase investor readiness. The opportunity to  participate comes after the MedTech startup was one of 10 awardees in last month’s Arizona Innovation  Challenge, a premier pitch competition that advances innovation and technology commercialization  opportunities in Arizona. 

The Cincinnati-based startup recently opened a second office in Phoenix in a strategic move to grow its  presence in Arizona. Last month, Sense Neuro Diagnostics announced that it had entered into a know-how  license agreement with the Mayo Clinic, and the startup is currently engaged with the Mayo Clinic and  Arizona State University MedTech Accelerator in Tempe, Arizona. 

Sense Neuro Diagnostics is developing innovative, non-invasive technology that can collect 360 data points  in 2.5 seconds to detect brain hemorrhage or stroke type. This technology has the potential to help first  responders, emergency department personnel, neuro ICU teams, and military field hospitals rapidly assess  and monitor traumatic brain injuries. 

“The Arizona Innovation Challenge and one of the largest business plan competitions in the country and a  great way for Sense to actively take steps toward commercialization,” says Geoffrey Klass, chief executive  officer, Sense Neuro Diagnostics. “Arizona is rich with resources and talented connections focused on  helping startups springboard to the next level, and Sense Neuro Diagnostics is pleased to be included in a  strong class of honorees.” 

More than 20 sites across the United States, Canada, and India are currently engaged in pivotal trials to  evaluate Sense Neuro Diagnostics’ in-hospital device, and five sites are evaluating its military field device.